Frequently Asked Questions
Who is ELREXFIO for?
ELREXFIO is a prescription medication used to treat adults with relapsed or refractory multiple myeloma who:
- have already received at least 4 treatment regimens, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody to treat their relapsed or refractory multiple myeloma, and
- their cancer has come back or did not respond to prior treatment
ELREXFIO was approved based on patient responses and durability of response. There are ongoing studies to confirm its clinical benefit. It is not known if ELREXFIO is safe and effective in children.
How does ELREXFIO work?
ELREXFIO is designed to bind to BCMA, a protein that is overexpressed on the surface of myeloma cells, and also to bind to the CD3 protein found on the surface of white blood cells, also called T cells.
This dual binding process activates T cells to target and destroy myeloma cells with BCMA on their surface. It may also harm a type of normal antibody-producing cell.
How was ELREXFIO studied?
ELREXFIO was studied in a clinical trial that included people with relapsed or refractory multiple myeloma who had received at least 4 treatment regimens.
The trial was divided into 2 groups:
Group A
This group included 97 people who had never previously tried a BCMA-directed therapy. Their cancer came back or did not respond to at least 4 treatment regimens, including:
- A proteasome inhibitor
- An immunomodulatory agent
- An anti-CD38 monoclonal antibody
Group B
This group included 63 people who had previously tried a BCMA-directed therapy. These people had previously taken a BCMA-directed antibody drug conjugate (ADC) treatment and/or a chimeric antigen receptor T cell (CAR T cell) treatment. Their cancer came back or did not respond to at least 4 treatment regimens, including:
- A proteasome inhibitor
- An immunomodulatory agent
- An anti-CD38 monoclonal antibody
What does a typical ELREXFIO dosing schedule look like?
ELREXFIO will be given to you by your healthcare provider as an injection under your skin (subcutaneous injection), usually in your stomach area (abdomen). Your thigh or another area of your body may also be used.
You will begin treatment with a “step-up” dosing schedule:
- For your first dose, you will receive a smaller “step-up” dose of ELREXFIO on day 1
- For your second dose, you will receive a larger “step-up” dose of ELREXFIO, which is usually given on day 4 of treatment
- For your third dose, you will receive the first treatment dose of ELREXFIO, which is usually given on day 8 of treatment
After completing the 2 “step-up” doses, you will likely begin weekly treatment with ELREXFIO at your healthcare provider’s office or another outpatient setting.
After 6 months of treatment, your healthcare provider will evaluate your progress and decide if an every other week dosing schedule could be right for you.
Where will I receive treatment?
You should be hospitalized for 48 hours after your first “step-up” dose and for 24 hours after your second “step-up” dose so that your healthcare provider can monitor you for certain side effects.
When you complete the “step-up” doses, you will likely begin weekly treatment with ELREXFIO at your healthcare provider’s office or another outpatient setting.
Does ELREXFIO have serious side effects?
ELREXFIO may cause serious, life-threatening side effects. These include cytokine release syndrome (CRS) and neurologic problems. Some other serious side effects include infections, decreased white blood cell counts, and liver problems. Your care team will monitor you for signs and symptoms of these side effects.
What are the most common side effects of ELREXFIO?
The most common side effects of ELREXFIO include tiredness, injection site reaction (such as redness, itching, pain, bruising, rash, swelling, and tenderness), diarrhea, muscle and bone pain, decreased appetite, rash, cough, nausea, and fever. The most common severe abnormal lab test results with ELREXFIO include decreased white blood cells, red blood cells, and platelets.
When is every other week dosing generally available for people taking ELREXFIO?
After 6 months of treatment, your healthcare provider will evaluate your progress and decide if an every other week dosing schedule could be right for you.
ELREXFIO is the first treatment of its kind to offer every other week dosing for patients who have achieved a partial response or better after 6 months of treatment.
What support is available to help me with my ELREXFIO treatment?
A Pfizer Patient Access Navigator can work directly with you and your care team to:
- Help you navigate your insurance coverage, including letting you and your care team know how much of your treatment is covered by insurance and what your out-of-pocket costs may be
- Provide treatment coordination by connecting eligible patients to independent organizations that provide free transportation or lodging for treatment-related appointments as well as confirming hospital discharge plans
- Support you during treatment by confirming logistics, providing appointment reminders, following up on insurance needs, and connecting you to a wide range of free resources
Are there financial assistance resources available to help me pay for my treatment?
If needed, Pfizer Oncology Together can help you find financial assistance options for your prescribed ELREXFIO, regardless of your insurance coverage.
